Oric Pharmaceuticals
Chelsea Chen is an accomplished scientist with extensive experience in preclinical development and drug metabolism. Currently serving as a Scientist at ORIC Pharmaceuticals since June 2016, Chelsea previously held the position of Associate Scientist II at Novartis from March 2015 to June 2016 and worked as a Research Associate at Quintara Discovery from July 2013 to March 2015. Chelsea holds a Master of Science in Data Science from The Johns Hopkins University and a Master of Science in Biology from San Francisco State University, complemented by a Bachelor of Science in Biotechnology from Dalian Polytechnic University.
Oric Pharmaceuticals
ORIC Pharmaceuticals is a privately held, clinical-stage oncology company focused on making cancer treatments more effective by addressing mechanisms of resistance. ORIC's lead asset, ORIC-101, is a potent and selective small-molecule antagonist of the glucocorticoid receptor. ORIC's pipeline targets other undisclosed mechanisms of oncology therapy resistance. ORIC's scientific founders are Drs. Charles Sawyers, MD, and Scott Lowe, PhD, who have strong records of discovering innovative treatments and targets in cancer. The company has assembled strong leadership and scientific teams and a board with extensive experience in drug development and financing. ORIC is funded by leading biotechnology investors, including The Column Group, Topspin Partners, OrbiMed Advisors, EcoR1 Capital, Fidelity Management & Research Company, Trinitas Capital, Foresite Capital, Taiho Ventures, Memorial Sloan Kettering, Kravis Investment Partners, NS Investment and City Hill Ventures. ORIC is headquartered in South San Francisco, California.